At least two experimental COVID-19 vaccines produced a T-cell response in participants in early-stage clinical trials, which may indicate a longer-lasting form of immunity than an antibody response. BioNTech BNTX, + 3.46% and Pfizer Inc. PFE, + 0.69% It said early Monday morning that an ongoing early-stage clinical trial for …
Read More »
Posted: Jul 14, 2020 at 6:23 pm ET Moderna headquarters in Cambridge, Massachusetts. fake pictures Moderna Inc.’s shares soared in the extended session Tuesday after the biotech company said its coronavirus vaccine candidate produced a “robust” immune system response in a larger group of people and the study will go …
Read More »
Text size Moderna’s headquarters in Cambridge, Massachusetts. Joseph Prezioso / AFP / Getty Images Moderna’s announcement of positive data about a Phase 1 trial of its Covid-19 vaccine in May was met with skepticism by some experts, who noted that the company had not included many details about the trial’s …
Read More »
Moderna Inc.’s shares soared in the extended session Tuesday after the biotech company said its coronavirus vaccine candidate produced a “robust” immune system response in a larger group of people and the study will go on to a decisive clinical trial in July. Results published in The New England Journal …
Read More »
Text size Joseph Prezioso / Getty Images Shares of Modern biotechnology fell 6.2% on Thursday afternoon after health news website Stat reported that the company was delaying the start of a Phase 3 trial of its experimental Covid-19 vaccine. The report, based on quotes from unidentified sources described as “investigators,” …
Read More »